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Abstract
Purpose To determine the biologic behavior and prog-
nostic factors of spinal cord astrocytoma, we reviewed
surgical and clinical outcomes. Due to the rarity of spinal
cord astrocytoma, there is a lack of research regarding this
type of tumor and malignant transformation.
Methods We retrospectively reviewed the data from all
patients on whom we performed spinal cord tumor removal
between 1983 and 2014. Twenty-six patients were patholog-
ically confirmed to have spinal cord astrocytoma or
glioblastoma. Surgical extent and disease progression were
confirmed by the surgeon based on operative findings, post-
operative MRI, and outpatient department (OPD) follow-up.
Results Pain or neurological deficit was the chief complaint
for all patients.WithMRI studies, there is a tendency for high-
grade astrocytomas to show as enhanced and heterogeneous
images.Twoof the low-grade astrocytomas showedmalignant
transformation over the course of 4 and 11 months, respec-
tively. The overall survival (OS) for low-grade astrocytoma
was 28–480 months (mean 156.38 months); the OS for high-
grade astrocytoma was 1–36 months (mean 12.00 months).
Conclusions Two of 12 low-grade cases showed malig-
nant transformations at 4 and 11 months, respectively,
based on pathological confirmation. With spinal cord
astrocytomas, enhanced MRI results appeared similar to
those of a malignant lesion. We suggest close observation
and image correlation of low-grade astrocytomas, even
when pathologically confirmed as low-grade. In this
review, we found that histologic grade is the most impor-
tant prognostic factor, although it is not always concordant
with biologic behaviors.
Keywords Spinal cord neoplasm  Astrocytoma 
Malignant glioma  Radiotherapy  Survival
Introduction
Spinal cord tumors comprise only 2–4 % of CNS neo-
plasms in adults, one-third of which are located intrame-
dullary [1–4]. Intramedullary spinal cord astrocytomas
account for 6–8 % of all primary spinal cord tumors [5–7],
indicating their rarity. Few investigations into the patho-
logic features, postoperative outcomes, surgical experi-
ence, or chemotherapy regimens have been published for
these tumors; [1, 8–10] therefore, information is lacking on
the common clinico-radio-pathologic features of spinal
cord astrocytomas. Low-grade histologic findings, which
include pilocytic astrocytomas, diffuse astrocytomas, and
pilomyxoid astrocytomas, are more common than high-
grade findings, such as anaplastic astrocytomas (AA) and
glioblastoma (GB) [4, 11, 12].
For treating low-grade primary spinal cord gliomas,
gross total resection is considered the gold standard when
possible and has an excellent local control rate. Additional
radiation therapy is recommended for cases of partial
resection. There is currently no gold standard treatment for
malignant primary spinal cord glioma [10].
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MRI plays an important role in predicting tumor type
before confirmation through histologic diagnosis, helping
to establish an appropriate treatment plan. MRI, particu-
larly contrast-enhanced imaging, not only shows the exact
locations and extensions of intramedullary tumors but also
differentiates between tumor cysts and tumor-related
benign fluid collection [13]. Specifically, astrocytomas
tend to have slightly fewer well-defined margins and are
more likely to be eccentrically located within the spinal
cord. Lesions on the spinal cord appear as isointense or
hypointense when viewed on Tl-weighted imaging and as
hyperintense on T2-weighted imaging; these lesions can be
enhanced with contrast despite their low histological grade
[11]. It is important to differentiate between benign and
malignant tumors before establishing a treatment plan for
spinal cord astrocytomas. Unfortunately, there are only a
sparse number of reports on radiologic differentiation
between benign and malignant spinal cord astrocytoma.
To investigate the radiologic findings, prognostic fac-
tors, pathologic features, postoperative outcome, and nat-
ural behavior patterns that are common with spinal cord
astrocytomas, we retrospectively reviewed 26 cases of
surgically verified spinal cord astrocytomas in patients who
visited our institute. We identified several astrocytoma-
specific associations with clinical behavior, MRI features,
and pathology. Our findings will be helpful in distin-
guishing between malignant and benign spinal cord astro-
cytomas, predicting prognosis, and performing an early
selection of the best treatment option and strategy.
Materials and methods
Patient selection
We retrospectively reviewed the medical records of 26
patients who were diagnosed with and surgically treated for
pathologically verified spinal cord astrocytoma at our
hospital from 1983 to 2014. Two patients experienced
malignant transformation; thus, our review included a
pathologic description of malignant transformation into
glioma. The study was approved by the Institutional
Review Board at the Human Research Protection Center of
our hospital.
Patient evaluation and data collection
Medical records were reviewed for age, sex, symptom
presentation, primary complaint, duration of chief com-
plaint prior to diagnosis, and preoperative and postopera-
tive neurological function status. Functional status was
retrospectively evaluated using the Nurick score (Table 1)
[14].
Tumor extension, location, and pathologic grade were
obtained from each patient’s radiological and pathological
records. Postoperative patients were followed-up with
enhanced-material MRI. Surgical extent and disease pro-
gression were confirmed on postoperative and follow-up
MRI. Microscopic preparations were reviewed, and tumors
were classified according to current WHO criteria as grade
I, II, III, or IV. One experienced neuropathologist con-
firmed the astrocytoma type from the slides for all cases in
this study; astrocytomas were classified as pilocytic astro-
cytoma, diffuse astrocytoma, anaplastic astrocytoma, or
glioblastoma.
Surgical procedures
All surgeries were performed with the patient in prone
position on the operating table. From 2010, somatosensory-
evoked potentials and motor-evoked potentials were mon-
itored and updated through out the operations. The sus-
pected tumor location region, as determined by MRI, was
marked with an 18G needle and a portable X-ray image,
and a laminectomy was performed over the region. A dura
incision and midline myelotomy were performed using an
intraoperative microscope. The operator decided the extent
of resection, relying on the tumor cleavage plane in the
operation field, and, from 2010, MEP changes were also
considered. Gross total tumor removal or subtotal tumor
removal was performed, with the exception of one patient
who underwent several diagnostic biopsies. For all patients,
a dura suture with meticulous attention toward hemostasis
was performed. A hemovac was inserted, and the wound
was closed layer-by-layer. All patients tolerated the oper-
ation well.
Adjuvant treatment
Nine of 14 patients who had a pathologically confirmed
high-grade astrocytoma received radiotherapy. One patient
diagnosed with a low-grade astrocytoma also received
Table 1 Nurick score for assessment of neurological function
Grade Description
0 Signs or symptoms of root involvement but without evidence
of spinal cord disease
1 Signs of spinal cord disease but no difficulty in walking
2 Slight difficulty in walking that did not prevent full-time
employment
3 Difficulty in walking that prevented full-time employment or
the ability to perform all housework but that was not severe
enough to require someone else’s help to walk
4 Able to walk with someone else’s help or the aid of a frame
5 Chair-bound or bedridden
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radiotherapy. Three patients underwent chemotherapy fol-
lowing their operation. Either temozolomide and vin-
cristine plus carboplatin or temozolomide alone were used
as chemotherapy agents.
Statistical methods
To analyze the relationships between behavior patterns and
tumor-grade characteristics (low-grade = WHO grades I
and II; high-grade = WHO grades III and IV), we per-
formed Mann–Whitney tests using the following variables:
age, sex, preoperative neurological status, postoperative
neurological status, duration of chief symptom complaint
until diagnosis, tumor location, tumor size, extent of
resection, and MRI findings. Additionally, Ki-67 index and
postoperative radiotherapy prognosis were analyzed. Cat-
egorical and grouped continuous variables with more than
four categories were aggregated according to clinical sig-
nificance or median value; these included patient age (C40
vs.\40), sex, tumor location (cervical/cervicothoracic vs.
thoracic/thoracolumbar), Ki-67 index (C5 vs.\5 %), and
surgical extent (total resection or gross total resection vs.
subtotal resection or partial resection).
Overall survival (OS) and progression-free survival
(PFS) were estimated using a Kaplan–Meier curve, and the
log-rank test was used to compare the survival distribu-
tions. OS was defined as the duration from the date of
diagnosis to the date of final follow-up or death. PFS was
defined as the duration from the date of diagnosis to the
date of tumor progression or death. A Cox proportional
hazards model was used to determine significant risk fac-
tors for death. For these models, we first performed uni-
variate analyses on all potential independent variables.
Next, we performed multivariate analyses using only the
variables that were significant in our univariate models.
All statistical tests were two-sided, and statistical sig-
nificance was defined as a p value of B0.05. All statistical
tests were conducted using SPSS, version 20.0, (Armonk,
NY, USA).
Results
Twenty-six patients (17 men, 9 women; mean age
38.9 years; range 14–76 years) were enrolled in this study.
Tumor locations included the cervical region (n = 11
cases), the thoracic region (n = 8 cases), the thoracolum-
bar region (n = 5 cases), and the cervicothoracic region
(n = 2 cases). The histologic grades of the tumors were
high-grade astrocytoma (n = 14 cases), which included
anaplastic astrocytoma and glioblastoma as well as two
patients who experienced malignant transformation from
diffuse astrocytoma to anaplastic astrocytoma, and low-
grade astrocytoma (n = 12 cases), which included pilo-
cytic astrocytoma and diffuse astrocytoma.
Preoperative neurological status and postoperative neu-
rological status were re-evaluated using the Nurick score
[14] and medical record data on preoperative neurological
status: three patients were classified as grade 1, six patients
were classified as grade 2, four patients were classified as
grade 3, ten patients were classified as grade 4, and three
patients were classified as grade 5.
Postoperative neurological status
No patients in our sample were classified as having a
Nurick grade of 1; however, four patients were grade 2,
five were grade 3, eight were grade 4, and nine were grade
5. There was a difference in preoperative neurological
status between patients who had a low-grade astrocytoma
and those who had a high-grade astrocytoma: 66.7 % of
low-grade patients had a neurologic grade of 1, 2, or 3,
while 71.4 % of high-grade patients had a neurological
grade of 4 or 5. There was also a difference in postopera-
tive neurological status between patients who had a low-
grade astrocytoma and those who had a high-grade astro-
cytoma: 58.3 % of low-grade patients had a neurological
grade of 1, 2, or 3, while 85.7 % of high-grade patients had
a neurological grade of 4 or 5. Overall, we found a sig-
nificant likelihood of better preoperative (p = 0.006) and
postoperative neurological status (p = 0.008) among low-
grade astrocytoma patients than among high-grade patients.
Duration of the chief complaint prior to diagnosiswas also
evaluated between low-grade astrocytoma patients and high-
grade patients. We found that the duration of low-grade
astrocytoma (mean 13.9 months; range 0.25–48 months)
was longer than the duration of high-grade astrocytoma
(mean 6.4 months; range 0.25–36 months; p = 0.009).
All of the low-grade astrocytoma patients underwent
gross total resection or total resection. Of the 14 high-grade
astrocytoma patients, 5 received a subtotal or partial
resection (p = 0.019; Tables 2, 4).
MRI findings
MRI revealed that 18 patients had a widened spinal cord, a
low signal in T1, and a high signal in T2. Four of seven
patients with low-grade astrocytoma showed T1 enhance-
ment, and 11 of 11 patients with high-grade astrocytoma
showed T1 enhancement with heterogeneous images.
Three of seven patients with low-grade astrocytoma and
eight of 11 patients with high-grade astrocytoma showed
cyst formation. Five of seven patients with low-grade
astrocytoma and one of 11 patients with high-grade
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astrocytoma had a syrinx formation. T1-enhanced results
and syrinx formation were significantly different between
patients with low-grade astrocytoma and those with high-
grade astrocytoma (p = 0.021 and p = 0.041, respectively;
Tables 3, 4).
Heterogeneity and cyst formation were not statistically
significant between patients with low-grade astrocytoma
and those with high-grade astrocytoma, based on the
Mann–Whitney test results (Table 4).
Ki-67 scores for low-grade astrocytoma patients fell
within the range of 1–4 % (mean 1.72 %), while the scores
for high-grade astrocytoma patients were within 5–30 %
(mean 18.25 %), which was a statistically significant dif-
ference (p\ 0.001).
The OS of low-grade astrocytoma patients was
28–480 months at the final follow-up (mean
156.38 months), while the OS of high-grade astrocytoma
patients was 1–36 months (mean 12.00 months), which
was a statistically significant difference (p\ 0.001).
PFS in low-grade astrocytoma patients was
12–480 months (mean 138.85 months), while PFS in high-
grade astrocytoma patients was 1–13 months (mean
6.64 months), which was a statistically significant differ-
ence (p\ 0.001).
Table 5 shows all of the candidate prognostic factors of
OS analyzed in the Cox hazards models. The univariate
analysis identified tumor grade [hazard ratio (HR) 4.685;
95 % confidential interval (CI) 2.201–9.974; p\ 0.001]
and tumor location (HR 3.002; CI 1.009–8.936; p = 0.048)
as being significantly associated with OS. Other factors
found to be significantly associated with OS on univariate
analysis were preoperative neurological status (HR 2.173;






















1 56 M 0.5 2 3 III T-L TR RT
(5400 cGy) ? CTx
10 7
2 75 F 2 3 4 III C STR RT (6300 cGy) 5 2
3 27 F 2 3 4 III C-T STR RT
(5400 cGy) ? CTx
34 12
4 25 M 0.5 4 4 II ? III C TR RT
(5220 cGy) ? CTx
22 11
5 22 F 0.5 5 5 IV C STR RT (4140 cGy) 8 3
6 46 F 0.25 2 2 II ? III T-L TR RT 12 4
7 76 F 3 4 5 IV C STR 9 9
8 64 M 1 5 5 IV C STR RT 2 1
9 19 F 1 4 4 IV C GTR RT 2 2
10 49 M 3 4 5 IV C-T TR 6 6
11 52 M 3 5 5 III T GTR 13 13
12 39 M 36 4 5 IV T TR 36 10
13 50 M 36 4 5 III C TR RT (4500 cGy) 13 13
14 41 M 1 4 5 III T GTR 12 3
15 23 M 8 3 3 I C TR 28 28
16 42 M 12 1 2 I C TR 43 43
17 46 F 36 1 2 I C TR 48 48
18 19 M 4 2 4 I T TR 48 48
19 29 M 12 4 4 II T TR RT (5000 cGy) 336 336
20 41 F 9 2 3 II T GTR 312 312
21 57 F 24 2 4 II C GTR 240 12
22 37 M 4 4 4 II T GTR 42 42
23 41 M 6 2 3 II T GTR 480 180
24 37 M 48 3 3 II C GTR 84 84
25 14 M 0.25 4 5 II T-L TR 72 72
26 22 M 9 1 2 II T-L TR 36 36
4070 Eur Spine J (2016) 25:4067–4079
123
CI 1.241–3.803; p = 0.007), postoperative neurological
status (HR 2.586; CI 1.314–5.092; p = 0.006), and surgical
extent (i.e., total resection/gross total resection vs. subtotal
resection/partial resection; HR 5.436; CI 1.517–19.473;
p = 0.009; Figs. 1, 2 and 3). The Ki-67 index score was a
significant negative predictor of overall survival (HR
1.078; CI 1.002–1.159; p = 0.045); however, our sample
for this variable included only 15 patients. Thus, our sta-
tistical power was low, and we thereby excluded the Ki-67
index from multivariate analysis.
Postoperative radiotherapy (RT) was performed in
patients with high-grade tumors. We distinguished between
low-grade and high-grade astrocytomas based on pathology
reports and then analyzed the high-grade group to deter-
mine the efficacy of RT, which was not statistically sig-
nificant (HR 2.855; CI 0.613–13.307; p = 0.182).
However, according to Fig. 4, a difference in OS was
observed. Overall survival of high-grade patients who had
undergone RT was shorter than that of those who had not.
Tumor grade, tumor location, surgical extent, and pre-
operative and postoperative neurological status were
included in the multivariate analysis. Tumor grade (HR
4.353; CI 1.356–13.980; p = 0.013) and location (HR
4.855; CI 1.187–19.851; p = 0.028) were the only vari-
ables that remained independently significant (Table 5).
Table 6 shows all of the candidate prognostic factors of
PFS analyzed in the Cox hazards model. On univariate
analysis, we found that tumor grade (HR 4.091; CI
1.617–10.346; p = 0.003), surgical extent (HR 5.926; CI
1.621–21.660; p = 0.007), and Ki-67 index (HR 1.085; CI
1.007–1.170; p = 0.031) were significantly associated with
PFS (Figs. 1, 2 and 3).
RT efficacy was not significant with regard to PFS in the
high-grade astrocytoma group (HR 2.130; CI
0.423–10.739; p = 0.360). However according to the
graph, the PFS of patients who had undergone RT was
shorter than that of those who had not (Fig. 4).
We performed a multivariate analysis of PFS prognostic
factors with tumor grade and surgical extent as our main
effect variables. Only tumor grade was independently
significant (HR 4.091; CI 1.617–10.346; p = 0.003;
Table 6).
Table 7 shows the characteristics of the two cases of
malignant pathologic changes. High-grade astrocytoma
was diagnosed in these two patients, who experienced
recurrence of diffuse astrocytoma 4 and 11 months after
receiving the initial diagnosis; these are referred to as cases
4 and 6, respectively.
In case 4, open biopsy was performed on March 26,
2013, and no tumor pathology was found. On September
10, 2013, gross total resection was performed, and diffuse
astrocytoma was pathologically confirmed. During reha-
bilitation, neurologic symptoms occurred, and MRI
revealed tumor recurrence. On April 9, 2014, gross total
resection was also performed, and pathologic high grade
astrocytoma was confirmed. Postoperative radiotherapy
was performed at 4500 cGy, in 25 fractions. Ultimately, a
high-grade glioma metastasized to the brain, and despite
concurrent chemoradiotherapy, the patient expired. In this
case, the undergrading could have been due to the small
proportions of the initial biopsy site, which was heteroge-
neous in nature, suggesting that the diagnosis was not
actually due to a malignant transformation but rather to a
primarily anaplastic astrocytoma that was undergraded.
In case 6, her chief complaint was right-leg tightness,
and MRI revealed a spinal cord tumor. On October 10,
2014, the tumor was removed via gross total resection, and
the pathology was a diffuse astrocytoma that showed mild
increased cellularity (Fig. 5a, 1009) with a fibrillary
background and moderate cytologic atypia (Fig. 5b,
4009). The Ki-67 labeling index in this case was approx-
imately 4 % (Fig. 5c, Ki-67, 1009). After 4 months, she
experienced a leg sensory change, and MRI showed tumor
recurrence. On February 3, 2015, gross total resection of
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the spinal cord tumor was performed. Contrary to previous
diffuse astrocytomas, anaplastic astrocytomas have a
moderately increased cellularity (Fig. 5d, 1009) with
marked cytologic atypia (Fig. 5e, 4009). Additionally, a
marked increase in the Ki-67 labeling index (approxi-
mately 20 %) was noted (Fig. 5f, Ki-67, 1009), suggesting
a malignant transformation from diffuse to high-grade
astrocytoma. In this case, there was focal enhancement on
MR images, and this enhancemet was increased when
pathologic high-grade glioma was confirmed (Table 7).
Discussion
Spinal cord astrocytoma is a rare tumor that has been rarely
studied and therefore lacks appropriate treatment guide-
lines. Malignant spinal cord astrocytomas have particularly
poor prognoses [7, 9, 15, 16]. Herein, we analyzed
behavioral patterns, prognosis factors, and treatment
options of spinal cord astrocytoma, and we explored dif-
ferences in these characteristics according to low-grade or
high-grade astrocytoma.
Table 4 Demographic data for
patients with low-or high-grade
astrocytoma
Factors Low-grade High-grade Total p value
Age 14–76 (38.9 years) 0.259
B40 7 (58.3 %) 5 (41.7 %) 12
[40 5 (35.7 %) 9 (64.3 %) 14
Sex 0.402
Male 9 (52.9 %) 8 (47.1 %) 17
Female 3 (33.3 %) 6 (66.7 %) 9
PreopNex 0.006*
1 3 0 3
2 4 2 6
3 2 2 4
4 3 7 10
5 0 3 3
PostopNex 0.008*
1 0 0 0
2 3 1 4
3 4 1 5
4 4 4 8
5 1 8 9
Duration of CC 0.25–48 (13.9) mo 0.25–36 (6.4) months 0.009*
Location 0.259
C, C-T 5 (35.7 %) 9 (64.3 %) 14
T, T-L 7 (58.3 %) 5 (41.7 %) 12
Surgical extent 0.019*
GTR, TR 12 (57.1 %) 9 (42.9 %) 21
STR 0 5 (100 %) 5
Tumor size 1–4.10 (2.48) cc 1–4.1 (2.46) cc 0.610
Ki-67 1–4 (1.72) % 5–30 (18.25) % \0.001
OS 28–480 (156.38) months 1–36 (12.00) months \0.001
PFS 12–480 (138.85) months 1–13 (6.64) months \0.001
MRI findings 7 11 18
T1-enhanced 4 11 15 0.021*
Heterogeneous 3 8 11 0.218
Cyst 1 5 6 0.105
Syrinx 5 1 6 0.041*
Asterisk indicates statistical significant data
PreopNex preoperative neurological status, PostopNex postoperative neurological status, OS overall sur-
vival, PFS progression-free survival
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Typically, high-grade astrocytomas involve a shorter
symptom duration prior to diagnosis than low-grade
astrocytomas, and there is also a statistically significant
difference in neurological status before and after surgery.
We found a statistically significant difference in the sur-
gical extent between low-grade and high-grade cases: total
or gross total resection was common in low-grade cases,
while subtotal or partial resection only occurred among
high-grade cases. This was likely due to the fact that high-
grade astrocytomas grow in a more rapid and invasive
manner than low-grade astrocytomas and are therefore
more challenging to resect.
In previous studies, histologic grade was emphasized
as a significant prognostic factor [6, 8, 16–18]. In our
study, histologic grade and tumor location were signifi-
cant prognostic factors of OS in both univariate and
multivariate analyses. Preoperative and postoperative
neurological status and surgical extent were also
Fig. 1 Tumor grade and overall survival/progression-free survival.
a Overall survival of low-grade and high-grade astrocytoma patients.
Continuous line low-grade astrocytoma, dotted line high-grade
astrocytoma. log-rank test p value\0.001. b Progression-free survival
of low-grade and high-grade astrocytoma patients. Continuous line
low-grade astrocytoma, dotted line high-grade astrocytoma. log-rank
test p value\0.001
Table 5 Cox regression
analysis of overall survival
Factor Univariate Multivariate
HR (95 % CI) p value HR (95 % CI) p value
Age 1.192 (0.424–3.352) 0.739 NT NT
Sex 1.143 (0.385–3.393) 0.810 NT NT
Tumor grade 4.685 (2.201–9.974) \0.001* 4.353 (1.356–13.980) 0.013*
Tumor location 3.002 (1.009–8.936) 0.048* 4.855 (1.187–19.851) 0.028*
Tumor size 1.086 (0.896–1.317) 0.400 NT NT
Ki-67 index 1.078 (1.002–1.159) 0.045* NT NT
PreopNex 2.173 (1.241–3.803) 0.007* 1.445 (0.550–3.794) 0.455
PostopNex 2.586 (1.314–5.092) 0.006* 1.162 (0.343–3.942) 0.809
Surgical extent 5.436 (1.517–19.473) 0.009* 0.935 (0.201–4.348) 0.932
Postop RT 2.855 (0.613–13.307) 0.182 NT NT
Asterisk indicates statistical significant data
CI Confidence interval, HR hazard ratio, PreopNex preoperative neurological status, Postop ex postoper-
ative neurological status, Postop RT postoperative radiotherapy, NT not tested
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statistically significant on univariate analysis yet not on
multivariate analysis. Histologic grade and surgical
extent were significant prognostic factors of PFS on
univariate analysis, while only histologic grade was a
significant independent predictor of PFS on multivariate
analysis.
Fig. 2 Surgical extent and overall and progression-free survival.
a Overall survival of patients who received total resection or gross
total resection vs. subtotal resection or partial resection. Continuous
line (gross) total resection, dotted line subtotal/partial resection. log-
rank test p value = 0.004. b Progression-free survival of patients who
received total resection or gross total resection vs. subtotal resection
or partial resection. Continuous line (gross) total resection, dotted line
subtotal/partial resection. log-rank test p value = 0.002
Fig. 3 Ki-67 index and overall and progression-free survival.
a Overall survival according to Ki-67 index. Continuous line Ki
index\5 %, dotted line Ki index C5 %. log-rank test p value\0.001.
b Progression-free survival according to Ki-67 index. Continuous line
Ki index \5 %, dotted line Ki index C5 %. log-rank test
p value = 0.002
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Eighteen of the 26 patients in our study had MRI data
that we could review. Many of the high-grade astrocy-
tomas were enhanced and heterogeneous, while the low-
grade astrocytomas were generally unenhanced and
homogenous on enhanced T1-weighted imaging. Spinal
cord enlargement usually occurs in response to an astro-
cytoma, and this can be observed on MRI, based on
homogenous or heterogeneous signal patterns along with
hypo- or iso-signal intensity on T1-weighted images or
hyper-signal intensity on T2-weighted images. We found
statistical differences in syrinx formation and T1
enhancement between low-grade and high-grade cases.
Cysts usually accompanied a high-grade astrocytoma.
Syrinxes, which form after a change in CSF flow [19, 20],
were observed in one of 11 high-grade cases and in five
of seven low-grade cases. This could be due to the fact
that low-grade tumors have fewer infiltrates than high-
grade tumors, resulting in a greater impact on CSF flow in
Fig. 4 Postoperative radiotherapy and overall and progression-free
survival in high-grade astrocytoma patients. a Overall survival of
high-grade astrocytoma patients who did not undergo postoperative
radiotherapy (solid line) was compared to patients who received
postoperative radiotherapy (dashed line), and the difference was not
significant (log-rank test p value = 0.15). b Progression-free survival
of high-grade astrocytoma patients who did not undergo postoperative
radiotherapy (solid line) was compared to patients who received
postoperative radiotherapy (dashed line), and the difference was not
significant (log-rank test p value 0.26)




HR (95 % CI) p value HR (95 % CI) p value
Age 1.577 (0.443–5.612) 0.482 NT NT
Sex 2.488 (0.716–8.639) 0.151 NT NT
Tumor grade 4.091 (1.617–10.346) 0.003* 3.473 (1.278–9.440) 0.015*
Tumor location 1.582 (0.446–5.615) 0.478 NT NT
Tumor size 0.964 (0.699–1.328) 0.821 NT NT
Ki-67 index 1.085 (1.007–1.170) 0.031* NT NT
PreopNex 1.396 (0.810–2.407) 0.230 NT NT
PostopNex 1.559 (0.798–3.045) 0.193 NT NT
Surgical extent 5.926 (1.621–21.660) 0.007* 2.041 (0.499–8.344) 0.321
Postop RT 2.130 (0.423–10.739) 0.360 NT NT
Asterisk indicates statistical significant data
CI Confidence interval, HR hazard ratio, PreopNex preoperative neurological status, PostopNex postop-
erative neurological status, Postop RT postoperative radiotherapy, NT not tested
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the spinal cord. More research on the effect of tumor
grade on syrinxes is needed.
All surgeries were performed by two experienced neu-
rosurgeons at a single institution, and all preoperative and
postoperative assessments were conducted using the same
analytic tools. Adams et al. reported that radical resection
was associated with extended survival for patients with AA
yet not those with GB [21]. McGirt et al. observed that
radical resection of AA was associated with a trend of
increased overall survival in nondisseminated AA cases.
Radical surgery and radiotherapy of GBM was associated
with poor survival [15]. Babu et al. showed that surgical
intervention is associated with a higher rate of neurological
complications [22], and Raco et al. also observed a
Fig. 5 Pathology comparison between diffuse astrocytoma and anaplastic astrocytoma. Diffuse astrocytoma: a 1009, b 4009, c Ki-67, 1009
(Ki-67 labeling). Anaplastic astrocytoma: d 1009, e 4009, f Ki-67, 1009 (Ki-67 labeling)
Table 7 Two cases of malignant pathologic changes
Case. 4 Case. 6
Age 25 46
Sex Male Female
Tumor location From cervical 2 to thoracic 2 From thoracic 12 to lumbar 1
Surgical extent Open biopsy (2013.03.26)
Gross total resection (2013.09.10)a
Gross total resection (2014.04.09)b
Gross total resection (2014.10.10)a
Gross total resection (2015.02.03)b
Tumor grade WHO grade II ? III WHO grade II ? III
Ki-67 index 3 ? 30 % 4 ? 20 %
MRI enhancement None ? enhance Focal enhance ? increased enhance
OS (months) 22 12
PFS (months) 11 4
Postop RTc 4500 cGy, 25 fraction 4140 cGy, 23 fraction
Metastasis Brain metastasis None
CCRTd Temodal ? IMRT (brain: 3750 cGy, 15 fraction,
Spine 3000 cGy, 12 fraction)
None
a The time of pathologic low grade confirmation
b The time of pathologic low-grade confirmation
c Postoperative radiotherapy after pathologic high-grade confirmation
d Concurrent chemoradiotherapy after brain metastasis
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worsening of the neurological deficit associated with the
extent of resections, noting that total surgical removal of
high-grade spinal cord lesions was rarely practicable [23].
Fakhreddine et al. and Innocenzia et al. the extent of
resection did not influence survival benefits within each
histological grade [6, 17]. Given that low-grade astrocy-
tomas were more likely to be grossly or totally resected
than high-grade astrocytomas, which were more likely to
be partially resected, surgical extent alone is too simplistic
as a prognostic factor. Consequently, we analyzed high-
grade astrocytomas alone using a Cox hazards analysis in
order to determine the relationships between surgical
extent and OS (HR 1.443; CI 0.408–5.105; p = 0.569) and
PFS (HR 2.098; CI 0.558–7.886; p = 0.273). In our study,
similar to those by Fakhreddine et al. and Innocenzia et al.
[6, 17], the extent of resection in high-grade spinal cord
glioma was not found to have a statistically significant
correlation with OS or PFS.
Eicker et al. suggested that the use of 5-ALA fluores-
cence could be beneficial, especially in intramedullary
gliomas [24]. Our surgeon also considered that the use of
5-ALA flourescence in intramedullary gliomas could be
helpful for surgical outcomes, likewise at the brain glioma
surgery area. However, there are restrictions on the use of
drugs that are not approved by the Korea Institute for
Health and Welfare in the Korea National Health Insur-
ance. In the future, the authors will proceed with spinal
cord tumor removal after using 5-ALA that has been
approved for research purposes.
Postoperative radiotherapy mainly targeted high-grade
astrocytoma cases, which significantly impacted survival,
although this result was highly likely to be selectively
biased. In a previous study, Merachnt et al. reported a
survival benefit from radiotherapy in a pediatric population
of high-grade spinal cord tumors [25], and Shirato et al.
suggested that postoperative conventional radiotherapy is
indicated after less than total resection of low-grade
astrocytomas and that radiocordectomy may be an option
for certain cases with high-grade astrocytic tumors [26].
However, Santi et al., Fakhreddine et al. and Adams et al.
did not observe any benefits of radiotherapy [1, 17, 21]. In
our study, OS and PFS in the high-grade group that
received RT appeared lower on the graph. Moreover, RT,
when used in conventional fractionation, can cause radia-
tion injury to the spinal cord [27, 28]. However, RT was
more often administered to patients who underwent
subtotal or partial resection depending on the postoperative
state, which was the reason for the potential selection bias
in our study.
Interpretations and reviews of pathology reports were
conducted by an experienced neuropathologist who had
conducted pathologic gene alteration of high-grade spinal
cord analyses for previous studies [29]. In case 4, we
performed the immunohistochemical stain. P53 was diffuse
strong positive, EGFR was positive (2?), and Ki-67 was
30 % in tumor cells. Similar to a previous study in which
malignant spinal cord astrocytoma usually disseminated
following neuraxis [9] and a recent study on low-grade
astrocytoma leptomeningeal dissemination to the brain
[30], our case also had EGFR positivity and neuraxis dis-
semination with malignant transformation. Promoter
methylation of the MGMT gene and IDH1 mutation were
not observed. Oligodendroglioma analysis indicated that 1p
LOH was positive and 19q LOH was negative. These
results show that malignant transformation of spinal cord
astrocytoma may involve different genetic alterations of
cranial astrocytoma.
The Ki-67 value as a progression marker has long been
thought to be a powerful morphologic predictor of the
biological behavior of glial neoplasms [31, 32]. Fifteen of
26 of our study patients had available Ki-67 values, which
were statistically significant as a prognostic factor.
A prior report found survival benefits of temozolomide
after radiotherapy in six patients with malignant primary
spinal cord tumors [10]. Fakhreddine et al. also reported that
among patients with infiltrative astrocytomas, chemotherapy
was significantly associatedwith improved PFS yet not OS on
multivariate analysis [17]. However, in our study, only three
patients who were diagnosed with high-grade astrocytoma
went through adjuvant chemotherapy, which yielded no sig-
nificant survival benefits during follow-up. On June 2, 2009,
Case 1 received 5400 cGy of adjuvant radiotherapy with
vincristine and carboplatin after total resection. We then
changed the chemoregimen to temozolomide after detecting
tumor progression on July 18, 2009. Case 1was discharged on
November5, 2009due to continued tumor progression.Case 2
underwent 6300 cGy of postoperative radiotherapy following
subtotal resection and was administered temozolomide as an
adjuvant chemotherapy. However, tumor progression was
detected 2 months later, and the patient died 5 months after
the initial diagnosis. Case 4 underwent two biopsies after the
detection of a spinal cord tumor and was diagnosed with dif-
fuse astrocytoma, for which the patient underwent total
resection. Next, the patient underwent 5400 cGy of RT, fol-
lowed by one cycle of temodal. The patient is currently in
OPD follow-up and has had an anaplastic astrocytoma for
11 months. The remaining patients did not receive
chemotherapy and were thus excluded from this analysis.
There were several limitations in our study. Due to the
rarity of spinal cord glioma, we had no choice but to per-
form a retrospective observational case series study at a
single institution. Additionally, there was a great deal of
heterogeneity in regards to the treatment of each patient,
even within each subgroup. As we have had no treatment
guidelines for spinal cord astrocytoma in the past decade,
this heterogeneity was inevitable in this retrospective
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study. In the future, with evidence-based proper guidelines,
a well-controlled prospective study will be performed. If
the periphery of the mass had been biopsied, the limited
amount of tissue that was commonly available for pathol-
ogy may have led to a lower-grade tumor diagnosis. Case 4
should be considered in light of the potential for sampling
error. As spinal cord tumor pathology was examined in a
small portion of tumor, pathologic confirmation of low-
grade glioma always revealed all fields of the tumor.
Considering sampling error and our experience of patho-
logic changes, we should consider a treatment plan that
correlates with MRI findings. Given that MRI enhancement
is correlated with malignant features, despite the pathology
of low-grade glioma, we suggest a more aggressive strat-
egy for postoperative treatment.
Conclusion
Pathologic grade is the strongest prognostic factor of OS
and PFS in spinal cord astrocytoma; however, it is not
always concordant with biologic behaviors. We observed
two cases of so-called malignant transformation at 4 and
11 months, respectively. For this reason, we suggest close
observation and image correlation of low-grade astrocy-
toma despite pathologic confirmation. Postoperative adju-
vant therapies, including radiotherapy and chemotherapy,
have not been well studied for astrocytoma, and more
research on genetic fields is needed.
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